1. Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
- Author
-
Williams DR, Evans AH, Fung VSC, Hayes M, Iansek R, Kimber T, O'Sullivan JD, and Sue CM
- Subjects
- Apomorphine administration & dosage, Australia epidemiology, Carbidopa administration & dosage, Drug Combinations, Humans, Levodopa administration & dosage, Parkinson Disease diagnosis, Antiparkinson Agents administration & dosage, Deep Brain Stimulation methods, Infusions, Parenteral methods, Infusions, Subcutaneous methods, Parkinson Disease drug therapy, Parkinson Disease epidemiology
- Abstract
In Australia 1% of individuals aged over 50 years have Parkinson disease (PD). Guidance for commencing device-assisted therapies (DAT) for PD in Australia was developed based on a review of European recommendations and their relevance to the local clinical setting. An online survey and teleconference discussions were held by a group of eight local movement disorder experts to develop consensus. Referral to a movement disorder specialist and consideration of DAT is appropriate when motor fluctuations cause disability or reduced quality of life, response to treatment is inconsistent or motor fluctuations and dyskinesias require frequent treatment adjustment without apparent benefit and levodopa is required four or more times daily. Three types of DAT are available in Australia for patients with PD: continuous subcutaneous apomorphine; continuous levodopa-carbidopa intestinal gel infusion; and deep brain stimulation. All improve consistency of motor response. The most important aspects when considering which DAT to use are the preferences of the patient and their carers, patient comorbidities, age, cognitive function and neuropsychiatric status. Patients and their families need to be provided with treatment options that are suitable to them, with adequate explanations regarding the recommendations and comparison of potential device-related complications. DAT are best managed, where possible, in a specialist centre with experience in all three types of therapy. Proactive and early management of symptoms during disease progression is essential to maintain optimally motor responses and quality of life in patients with PD., (© 2017 Royal Australasian College of Physicians.)
- Published
- 2017
- Full Text
- View/download PDF